Read by QxMD icon Read

"Conjugated estrogen"

Aazam Parnan Emamverdikhan, Nahid Golmakani, Sayyed ASajadi Tabassi, Malihe Hassanzadeh, Nooriyeh Sharifi, Mohammad Taghi Shakeri
BACKGROUND: Menopause is associated with various complications such as depression, sleep disorders, and genitourinary atrophy. Vaginal atrophy occurs due to the loss of steroid hormones, and its major symptoms include vaginal dryness, itching, dyspareunia, and bleeding after intercourse. According to the literature, vitamin E plays a key role in estrogen stability. The aim of this study was to compare the effects of vitamin E suppositories and conjugated estrogen vaginal cream on vaginal atrophy...
September 2016: Iranian Journal of Nursing and Midwifery Research
Mahmood Soveid, Ghanbar Ali Rais-Jalali
Congenital adrenal hyperplasia comprises a group of disorders resulting from defects in enzymes required for the synthesis of cortisol. The clinical presentation depends on the specific enzyme defect. We report a rare case of congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency. A 26-year-old female patient referred with hypertension and hypokalemia. She also had primary amenorrhea and lack of sexual development. The karyotype was 46, XY. Hormonal evaluation showed low serum levels of all steroid hormones, requiring alpha-hydroxylation, which included cortisol, 17 alpha-hydroxy progesterone, dehydroepiandrosterone sulfate, estradiol, and testosterone...
November 2016: Iranian Journal of Medical Sciences
Lucy Abraham, Andrew G Bushmakin, Erika Dragon, Barry S Komm, JoAnn V Pinkerton
OBJECTIVE: Determine the direct and indirect effects of conjugated estrogens/bazedoxifene (CE/BZA) treatment on menopause-specific quality of life in a post-hoc analysis of 2 phase 3 Selective estrogens, Menopause, And Response to Therapy (SMART-1, SMART-2) trials. STUDY DESIGN: Data from participants in SMART-1 and SMART-2 who received CE 0.45mg/BZA 20mg, CE 0.625mg/BZA 20mg, or placebo were analyzed, including week 12 data from 1274 healthy postmenopausal women in SMART-1 and pooled week 1-4 and 9-12 data from 332 women with moderate to severe vasomotor symptoms (≥7 HFs/d or ≥50/wk) in SMART-2...
December 2016: Maturitas
Nanette Santoro, Amanda Allshouse, Genevieve Neal-Perry, Lubna Pal, Rogerio A Lobo, Frederick Naftolin, Dennis M Black, Eliot A Brinton, Matthew J Budoff, Marcelle I Cedars, N Maritza Dowling, Mary Dunn, Carey E Gleason, Howard N Hodis, Barbara Isaac, Maureen Magnani, JoAnn E Manson, Virginia M Miller, Hugh S Taylor, Whitney Wharton, Erin Wolff, Viola Zepeda, S Mitchell Harman
OBJECTIVE: The objective of the present study was to compare the efficacy of two forms of menopausal hormone therapy in alleviating vasomotor symptoms, insomnia, and irritability in early postmenopausal women during 4 years. METHODS: A total of 727 women, aged 42 to 58, within 3 years of their final menstrual period, were randomized to receive oral conjugated estrogens (o-CEE) 0.45 mg (n = 230) or transdermal estradiol (t-E2) 50 μg (n = 225; both with micronized progesterone 200 mg for 12 d each mo), or placebos (PBOs; n = 275)...
October 24, 2016: Menopause: the Journal of the North American Menopause Society
Narathorn Suwanvesh, Jittima Manonai, Areepan Sophonsritsuk, Wichai Cherdshewasart
OBJECTIVES: To compare the effects of a 12-week treatment with Pueraria mirifica (PM) gel or a conjugated estrogen cream on vaginal maturation index, vaginal symptom score, vaginal health assessment score, and vaginal flora in postmenopausal women. METHODS: In a prospective, noninferiority, randomized controlled study, 82 postmenopausal women with at least one vulvovaginal symptom, that is, dryness, soreness, irritation, dyspareunia, or discharge, were recruited...
October 3, 2016: Menopause: the Journal of the North American Menopause Society
David F Archer, Ellen W Freeman, Barry S Komm, Kelly A Ryan, Ching-Ray Yu, Sebastian Mirkin, JoAnn V Pinkerton
OBJECTIVES: Conjugated estrogens/bazedoxifene (CE/BZA) reduced menopause-related hot flashes (HFs) in the Selective estrogens, Menopause, And Response to Therapy (SMART) trials. This post hoc pooled analysis of SMART-1 and -2 further characterized effects of CE/BZA on HFs in the overall population and patient subgroups. METHODS: Data from two randomized, double-blind, placebo- and active-controlled, phase 3 studies were pooled for nonhysterectomized postmenopausal women with moderate/severe HFs given CE 0...
September 27, 2016: Journal of Women's Health
Ai-Jun Sun, Ya-Ping Wang, Bei Gu, Ting-Ping Zheng, Shou-Qing Lin, Wen-Pei Bai, Yang Wei, Shao-Fen Zhang, Ying Zhang
OBJECTIVE: To evaluate the efficacy and safety of Heyan Kuntai Capsule (, HYKT) and hormone therapy (HT) on perimenopausal syndromes (PMSs). METHODS: From 2005 to 2008, 390 women with PMSs were recruited from 4 clinic centers. The inclusion criteria included ages 40 to 60 years, estradiol (E2) below 30 ng/L, and follicle stimulating hormone (FSH) above 40 IU/L, etc. The patients were randomly assigned to HYKT group or HT group by random number table method, administrated HYKT or conjugated estrogen with/without medroxyprogesterone acetate tablets for 12 months...
September 20, 2016: Chinese Journal of Integrative Medicine
P Hadji, K A Ryan, C-R Yu, S Mirkin, Barry S Komm
OBJECTIVES: To evaluate the efficacy of conjugated estrogens/bazedoxifene (CE/BZA) on bone mineral density (BMD), bone turnover markers (BTM), and menopause-specific quality of life (MENQOL) in European women. METHODS: Data through 12 months were pooled from two double-blind, randomized, controlled trials in non-hysterectomized postmenopausal women who received CE/BZA or placebo. Women from European study sites with evaluable BMD (n = 60), BTM (n = 56), and MENQOL questionnaire (n = 236) data were included and compared with 1523 women from US study sites (n = 730 with evaluable data for bone outcomes)...
October 2016: Climacteric: the Journal of the International Menopause Society
W Xue, A J Sun, T P Zheng, J F Jiang, Y P Wang, Y Zhang, F L Chen, Y Deng, Y F Wang
OBJECTIVE: To explore the effects of five different therapy in women at early stage of menopause on menopausal symptoms, quality of Life and cardiovascular risk factors. METHODS: A total of 140 women at early stage of menopause were randomly divided into five groups. Thirty women took Conjugated estrogen and medroxyprogesterone acetate(CEE+ MPA) sequential therapy, 27 women took estradiol valerate and medroxyprogesterone acetate(E2V+ MPA) sequential therapy, 26 women took estradiol valerate and Progesterone Soft Capsules(E2V+ P) sequential therapy, 30 women took Kuntai capsule, and 27 took Cohosh extract...
August 2, 2016: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Fatemeh Seyyedi, Mahmoud Rafiean-Kopaei, Sepideh Miraj
INTRODUCTION: Several causes can disturb the quality of life in postmenopausal women. Stress, urinary incontinence is one of the factors that can influence the quality of life of women, since they evade social activities and limit their behavior. Vulvovaginal disorders adversely impacts sexual action, psychosocial health, and partner relationships. AIM: The aim of this study was to examine the therapeutic properties of vaginal cream of royal jelly and estrogen on quality of life, sexual and urinary problems in postmenopausal women...
May 2016: Journal of Clinical and Diagnostic Research: JCDR
Risa Kagan, Barry S Komm, Kelly A Ryan, Joanne Lavenberg, Ching-Ray Yu, JoAnn V Pinkerton
OBJECTIVE: The aim of the study was to determine the time course of effect with conjugated estrogens/bazedoxifene (CE/BZA) in nonhysterectomized postmenopausal women in five phase 3 trials. METHODS: This post hoc analysis identified when CE 0.45 mg/BZA 20 mg and CE 0.625 mg/BZA 20 mg first achieved a statistically significant difference (P < 0.05) versus placebo in individual trials and the duration the difference persisted for prespecified efficacy endpoints...
July 18, 2016: Menopause: the Journal of the North American Menopause Society
R Hurtado, M Celani, S Geber
OBJECTIVE: To evaluate the effect of short-term hormone replacement therapy with 0.625 mg conjugated estrogens daily on endothelial function of healthy postmenopausal women, using flow-mediated dilation (FMD) of the brachial artery. METHODS: We performed a double-blinded, randomized, controlled trial over 3 years. Randomization was performed using computer-generated sorting. All participants were blinded to the use of conjugated equine estrogens (CEE) or placebo and FMD was assessed by a blinded examiner, before and after 28 days of medication...
October 2016: Climacteric: the Journal of the International Menopause Society
J Christopher Gallagher, Santiago Palacios, Kelly A Ryan, Ching-Ray Yu, Kaijie Pan, David L Kendler, Sebastian Mirkin, Barry S Komm
OBJECTIVE: Conjugated estrogens/bazedoxifene reduces vasomotor symptoms and prevents postmenopausal bone loss without stimulating the breast and endometrium. We analyzed changes in bone mineral density (BMD) and bone markers using pooled data from two phase-3 trials. METHODS: Selective Estrogens, Menopause, and Response to Therapy (SMART)-1 and SMART-5 were randomized, double-blind, placebo- and active-controlled studies conducted in postmenopausal nonhysterectomized women...
October 2016: Menopause: the Journal of the North American Menopause Society
JoAnn V Pinkerton, Lucy Abraham, Andrew G Bushmakin, Joseph C Cappelleri, Barry S Komm
OBJECTIVE: This study characterizes and quantifies the relationship of vasomotor symptoms (VMS) of menopause with menopause-specific quality of life (MSQOL) and sleep parameters to help predict treatment outcomes and inform treatment decision-making. METHODS: Data were derived from a 12-week randomized, double-blind, placebo-controlled phase 3 trial that evaluated effects of two doses of conjugated estrogens/bazedoxifene on VMS in nonhysterectomized postmenopausal women (N = 318, mean age = 53...
October 2016: Menopause: the Journal of the North American Menopause Society
JoAnn V Pinkerton, Andrew G Bushmakin, Lucy Abraham, Joseph C Cappelleri, Barry S Komm
OBJECTIVE: Conjugated estrogens/bazedoxifene (CE/BZA) is indicated to treat moderate/severe menopausal vasomotor symptoms and prevent postmenopausal osteoporosis. This analysis examines the impact of the most bothersome vaginal symptom at baseline on effects of CE/BZA. METHODS: This post hoc analysis used data from a 12-week clinical trial of nonhysterectomized postmenopausal women (n = 664) randomly assigned to double-blind treatment with CE/BZA (0.45/20 mg and 0...
October 2016: Menopause: the Journal of the North American Menopause Society
Ajaz Ahmad, Sujan Kumar Mondal, Basit Latief Jan, Debabrata Mukhopadhyay, Rajkumar Banerjee, Khalid M Alkharfy
A lipid-conjugated, estrogenic derivative molecule, ESC8, compared with other estrogenic molecules, encourages cell death in both ER-positive and ER-negative breast cancer cells. A rapid and highly sensitive assay method has been developed and validated for the estimation of a ESC8 in rat plasma using liquid chromatography coupled with mass spectrometry under positive-ion mode with electrospray ionization. The sample process includes using methanol for precipitation of ESC8 and dextromethorphan (internal standard, IS) from plasma...
December 2016: Biomedical Chromatography: BMC
Richard J Santen, Yan Song, Ji-Ping Wang, Wei Yue
The first tissue-selective estrogen complex (TSEC), consisting of a combination of a conjugated equine estrogen (CEE) and bazedoxifene (BZA), has been approved for treatment of the menopause in the USA and European Union. We have postulated that this TSEC might block the estrogenic effects of CEE on breast tissue and thereby prevent breast cancer growth. This manuscript, representing a presentation at a Festschrift honoring Evan Simpson, reviews our published data BZA blocked the in vitro effects of both estradiol and CEE on cell growth and gene expression in MCF-7 cells...
May 9, 2016: Journal of Steroid Biochemistry and Molecular Biology
Chi-Yan Tsai, Chun-Wei Li, Jie-Ren Li, Bo-Han Jang, Shu-Hui Chen
Steroid ligands can easily diffuse through the cell membrane and this property makes it feasible to be used for in-situ staining of the nuclear receptors. However, nonspecific binding of the internalized ligand probe with the cellular components has caused serious interferences for the detection of receptor-expressing cells. We report a novel gold nanocluster (AuNC)-conjugated estrogen probe that can eliminate nonspecific internalization and accelerate nuclear localization to achieve selective and rapid detection of estrogen receptors (ERs) in live cells...
July 2016: Journal of Fluorescence
JoAnn V Pinkerton, James H Pickar, Kelly A Ryan, Ching-Ray Yu, Sebastian Mirkin, Barry S Komm
OBJECTIVE: The aim of the study was to compare efficacy of conjugated estrogens (CE)/bazedoxifene (BZA) for treatment of menopausal symptoms and prevention of postmenopausal osteoporosis in minorities (black/Hispanic) versus whites. METHODS: In a post hoc analysis, data were pooled from 3,424 white or minority nonhysterectomized postmenopausal women randomized to CE 0.45 or 0.625 mg/BZA 20 mg or placebo in four double-blind, phase 3 Selective Estrogens, Menopause, and Response to Therapy (SMART) trials...
June 2016: Menopause: the Journal of the North American Menopause Society
Risa Kagan, Steven R Goldstein, James H Pickar, Barry S Komm
Menopausal symptoms (eg, hot flushes and vaginal symptoms) are common, often bothersome, and can adversely impact women's sexual functioning, relationships, and quality of life. Estrogen-progestin therapy was previously considered the standard care for hormone therapy (HT) for managing these symptoms in nonhysterectomized women, but has a number of safety and tolerability concerns (eg, breast cancer, stroke, pulmonary embolism, breast pain/tenderness, and vaginal bleeding) and its use has declined dramatically in the past decade since the release of the Women's Health Initiative trial results...
2016: Therapeutics and Clinical Risk Management
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"